Basic Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Exp Med. Jun 20, 2025; 15(2): 102897
Published online Jun 20, 2025. doi: 10.5493/wjem.v15.i2.102897
Diarylpentanoid, a curcumin analog, inhibits malignant meningioma growth in both in vitro and in vivo models
Anna Terasawa, Kazuhiro Shimazu, Hiroshi Nanjo, Masatomo Miura, Hiroyuki Shibata
Anna Terasawa, Department of Clinical Oncology, Akita University, Akita 010-8543, Japan
Kazuhiro Shimazu, Hiroyuki Shibata, Department of Clinical Oncology, Akita University Graduate School of Medicine, Akita 010-8543, Japan
Hiroshi Nanjo, Department of Pathology, Akita University, Akita 010-8543, Japan
Masatomo Miura, Department of Pharmacokinetics, Graduate School of Medicine, Akita University, Akita, Japan
Author contributions: Terasawa A, Shimazu K, Shibata H designed and coordinated the study; Terasawa A, Shimazu K, Shibata H, Miura M, Shibata H performed the experiments, acquired and analyzed data; Terasawa A, Shimazu K, Nanjo H, Miura M, Shibata H interpreted the data; Terasawa A, Shibata H wrote the manuscript; all authors approved the final version of the article.
Supported by TAIHO Pharmaceutical, No. AS2023A000122715; and Nippon Kayaku, No. NKCS20230416001.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board at Akita University.
Institutional animal care and use committee statement: All animal experiments conformed to the internationally accepted principles for the care and use of laboratory animals. This study proposal received approval from the Research Ethics Committee at Akita University: No. b-1-0440.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hiroyuki Shibata, MD, PhD, Professor, Department of Clinical Oncology, Akita University Graduate School of Medicine, Hondo 1-1-1, Akita 010-8543, Japan. hiroyuki@med.akita-u.ac.jp
Received: November 1, 2024
Revised: December 31, 2024
Accepted: January 21, 2025
Published online: June 20, 2025
Processing time: 166 Days and 7.5 Hours
Core Tip

Core Tip: Malignant meningiomas have a poor prognosis, but drug development is limited due to their rarity. The curcumin analog GO-Y030 showed approximately 10-16 times stronger inhibitory effects than curcumin on IOMM-Lee and HKBMM cell lines, in vitro. Intraperitoneal administration of GO-Y030 also significantly inhibited the growth of malignant meningiomas, IOMM-Lee inoculated in nude mouse models. GO-Y030 significantly inhibited hepatocyte growth factor, nuclear factor kappa B, and N-cadherin, which contribute to epithelial-mesenchymal transition.